Developer of an extracellular matrix-targeting therapeutic platform intended to treat cancer. The company's platform offers a unique combination of antibodies and small molecules to target specific proteins and is more effective and less toxic than traditional cancer therapies, enabling the healthcare industry to target a wide range of cancer types with a single therapeutic.